![]() At diagnosis, 87.1% had DLBCL alone, and 12.9% had concurrent DLBCL and indolent NHL. In this study, Wang and colleagues looked at 1,324 patients with newly diagnosed DLBCL treated with immunochemotherapy. This exclusion has made it unclear what the best treatment strategy is for these cases. In these cases, patients are typically treated for the most aggressive form of lymphoma present and are generally excluded from clinical trials. In contrast, other clinicians consider these cases as composite lymphoma, if the DLBCL and indolent NHL components are in the same nodal or extranodal tissue, or discordant lymphoma, if they are found in different tissue biopsies.” “Therefore, some clinicians consider concurrent DLBCL and indolent lymphoma as early transformation of a previously undiagnosed indolent lymphoma. “FL and other indolent lymphomas can undergo histological transformation into a more aggressive lymphoma such as DLBCL,” Wang and colleagues explained. Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) and a concurrent lymphoma predominantly had a disease histology similar to the GCB (germinal center B-cell–like) subtype of the disease, according to a new study published in Blood.Īdditionally, outcomes for these patients were identical to those of patients with GCB DLBCL alone, reported Yucai Wang, MD, PhD, of Mayo Clinic, Rochester, Minn., and colleagues.Īccording to the study, between 10% and 15% of patients with newly diagnosed DLBCL will also have concurrent indolent lymphoma, such as follicular lymphoma (FL) or non-Hodgkin lymphoma (NHL), in the bone marrow.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |